Takeda Pharmaceutical Co. Chief Executive Officer Christophe Weber pushed back against dissident shareholders seeking to stop the drugmaker's acquisition of Shire PLC, saying he won't release minutes of boardroom discussions.
A group including members of Takeda's founding family opposes the planned $62 billion (about ¥7 trillion) acquisition of the U.K.-listed biotech, which would rank as the biggest overseas acquisition ever by a Japanese company.
The investors plan to sue Takeda in a bid to obtain details of the board talks leading up to the May deal, trade publication DealReporter said last week.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.